title: [Clinical investigation of reduced-dose voriconazole on primary prevention in invasive fungal disease after allogeneic hematopoietic stem cell transplantation].
abstract: OBJECTIVE
  To investigate the efficacy and tolerability of intravenous voriconazole on primary prevention in invasive fungal disease (IFD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  
  
  METHODS
  At the time of conditioning regimen, patients without IFD was intravenously administered with voriconazole at a dose of 100 mg two times per day until neutrophils greater than 0.5×10⁹/L. Patients treated with oral fluconazole, 200 mg per day, were control group. The incidence and risk factors of IFD and side effects of medicines were evaluated.
  
  
  RESULTS
  Of the total 227 patients, 33 (14.54%) had IFD within 3 months after allo-HSCT. There was significant difference on overall survival between patients with or without IFD by Kaplan-Meier survival curve (P=0.029). Of the 83 cases with intravenous voriconazole, 7 cases occurred IFD (8.43%). In contrast, the incidence of IFD in control group was 18.06% (26 out of 144). There was remarkable difference between the two groups (P=0.048). But there was no significant difference on risk factors of IFD between the two groups. In addition, the incidence of liver function abnormalities between the two groups was no difference. The ratio of auditory hallucination and visual impairment induced by voriconazole was not high.
  
  
  CONCLUSIONS
  Intravenous voriconazole on primary prevention for IFD after allo-HSCT is much better than oral fluconazole with well tolerability and satisfactory efficacy.
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Zhixiang
authors: Z
authors: Qiu
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Hanyun
authors: H
authors: Ren
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Xinan
authors: X
authors: Cen
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Jinping
authors: J
authors: Ou
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Weilin
authors: W
authors: Xu
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Mangju
authors: M
authors: Wang
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Lihong
authors: L
authors: Wang
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Yujun
authors: Y
authors: Dong
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Yuan
authors: Y
authors: Li
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Wei
authors: W
authors: Liu
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Yuhua
authors: Y
authors: Sun
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Zeyin
authors: Z
authors: Liang
authors: Department of Hematology, the First Hospital of Peking University, Beijing 100034, China.
authors: Qian
authors: Q
authors: Wang
mesh_terms: D061605:Administration, Intravenous; D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000209:etiology / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control; D016896:Treatment Outcome; D065819:Voriconazole / Q000008:administration & dosage* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D015725:Fluconazole; D065819:Voriconazole